https://doi.org/10.4081/hmr.v2i5.728

Monoclonal antibodies (update): CD20, rituximab

Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Published: June 23, 2009
Abstract Views: 184
PDF: 121
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

C Hagenbeek
support@pagepress.org
Without any doubt, in the past 10 years Rituximab has caused a breakthrough in the prognosis of patients with both indolent and aggressive NHL. After it was shown that Rituximab as a single agent had significant activity in concert with a most favourable toxicity profile, the combination with appropriate chemotherapy showed not only an improved response rate and progression free survival, but – most strikingly – a significantly better overall survival. This has been particularly impressive in patients with advanced follicular NHL, in which group OS could not be improved during the past 30 years despite many attempts employing different treatment modalities (Marcus and Hagenbeek, 2007).

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Hagenbeek, C. (2009). Monoclonal antibodies (update): CD20, rituximab. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.728
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).